The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer-Reference-Cited by-同舟云学术

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer

Published:2004-12 Issue: Volume:31 Page:106-146
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Robert Nicholas J.,Vogel Charles L.,Henderson I. Craig,Sparano Joseph A.,Moore Melvin R.,Silverman Paula,Overmoyer Beth A.,Shapiro Charles L.,Park John W.,Colbern Gail T.,Winer Eric P.,Gabizon Alberto A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference305 articles.

1. Is breast cancer survival improving?;Giordano;Cancer,2004

2. Does chemotherapy improve survival in advanced breast cancer? A statistical overview;A’Hern;Br J Cancer,1988

3. Palliative effect of chemotherapy;Geels;J Clin Oncol,2000

4. Combination chemotherapy in hormone resistant breast cancer;Cooper;Proc Am Assoc Cancer Res,1969

5. Adjuvant chemotherapy of breast cancer;Cooper;Cancer,1979

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review;Breast Cancer: Targets and Therapy;2024-04

2. A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins;Scientific Reports;2024-03-01

3. Industrialization’s eye view on theranostic nanomedicine;Frontiers in Chemistry;2022-08-19

4. New challenges in the use of nanomedicine in cancer therapy;Bioengineered;2022-01-01

5. Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors;OncoTargets and Therapy;2021-05